Visceral Leishmaniasis Recent Advances in Diagnostics and Treatment Regimens

被引:123
|
作者
van Griensven, Johan [1 ]
Diro, Ermias [2 ]
机构
[1] Inst Trop Med, Dept Clin Sci, Natl Str 155, B-2000 Antwerp, Belgium
[2] Univ Gondar, Dept Internal Med, POB 196, Gondar, Ethiopia
关键词
Visceral leishmaniasis; Diagnosis; Treatment; DIRECT AGGLUTINATION-TEST; HUMAN-IMMUNODEFICIENCY-VIRUS; LIPOSOMAL AMPHOTERICIN-B; HIV-INFECTED PATIENTS; COINFECTED PATIENTS; SODIUM STIBOGLUCONATE; ETHIOPIAN POPULATION; PERIPHERAL-BLOOD; HIGH PREVALENCE; KALA-AZAR;
D O I
10.1016/j.idc.2018.10.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Diagnostic advances in visceral leishmaniasis include the development of the rK39 and rK28 rapid diagnostic test. The direct agglutination test is also increasingly used, as well as conventional and real-time polymerase chain reaction, which also performs well on peripheral blood. The choice of treatment for visceral leishmaniasis depends on the geographic region where the infection is acquired. Liposomal amphotericin B is generally found to be safe and effective in most endemic regions of the world; antimonials still remain to be the most effective in eastern Africa despite its high toxicity. Combination therapy is increasingly explored. Immunosuppressed patients require adapted diagnostic and therapeutic strategies.
引用
收藏
页码:79 / +
页数:22
相关论文
共 50 条
  • [41] Treatment of Visceral Leishmaniasis
    Moore, E. M.
    Lockwood, D. N.
    JOURNAL OF GLOBAL INFECTIOUS DISEASES, 2010, 2 (02) : 151 - 158
  • [42] Treatment of visceral leishmaniasis
    Sundar, S
    Rai, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (16) : 2821 - 2829
  • [43] Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh
    Mondal, Dinesh
    Kumar, Amresh
    Sharma, Abhijit
    Ahmed, Moshtaq Mural
    Hasnain, Md. Golam
    Alim, Abdul
    Huda, M. Mamun
    Rahman, Ridwanur
    Alvar, Jorge
    Ahmed, Be-Nazir
    Haque, Rashidul
    PLOS NEGLECTED TROPICAL DISEASES, 2019, 13 (08):
  • [44] Treatment of visceral leishmaniasis
    Shyam Sundar
    Medical Microbiology and Immunology, 2001, 190 : 89 - 92
  • [45] Nanoparticles for the treatment of visceral leishmaniasis: review
    Natália Silva de Santana
    Luciana Betzler de Oliveira de Siqueira
    Tatielle do Nascimento
    Ralph Santos-Oliveira
    Ana Paula dos Santos Matos
    Eduardo Ricci-Júnior
    Journal of Nanoparticle Research, 2023, 25
  • [46] Nanoparticles for the treatment of visceral leishmaniasis: review
    de Santana, Natalia Silva
    de Siqueira, Luciana Betzler de Oliveira
    do Nascimento, Tatielle
    Santos-Oliveira, Ralph
    Matos, Ana Paula dos Santos
    Ricci-Junior, Eduardo
    JOURNAL OF NANOPARTICLE RESEARCH, 2023, 25 (02)
  • [47] Recent advances in post-kala-azar dermal leishmaniasis
    Mondal, Dinesh
    Khan, Md Gulam Musawwir
    CURRENT OPINION IN INFECTIOUS DISEASES, 2011, 24 (05) : 418 - 422
  • [48] Miltefosine for Visceral and Cutaneous Leishmaniasis: Drug Characteristics and Evidence-Based Treatment Recommendations
    Monge-Maillo, Begona
    Lopez-Velez, Rogelio
    CLINICAL INFECTIOUS DISEASES, 2015, 60 (09) : 1398 - 1404
  • [49] Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan
    Thornton, Sheila J.
    Wasan, Kishor M.
    Piecuch, Anna
    Lynd, Larry L. D.
    Wasan, Ellen K.
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2010, 36 (11) : 1312 - 1319
  • [50] Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009
    Rosenthal, E.
    Delaunay, P.
    Jeandel, P. -Y.
    Haas, H.
    Pomares-Estran, C.
    Marty, P.
    MEDECINE ET MALADIES INFECTIEUSES, 2009, 39 (10): : 741 - 744